参考文献/References:
[1] Scowcroft AC,Lee S,Mant J. Thromboprophylaxis of elderly patients with AF in the UK:an analysis using the General Practice Research Database (GPRD) 2000-2009[J]. Heart,2013,99(2):127-132.
[2] Laux V,Perzborn E,Kubitza D,et al. Preclinical and clinical characteristics of rivaroxaban:a novel,oral,direct factor Xa nhibitor[J]. Semin Thromb Hemost,2007,33(5):515-523.
[3] 陈伟伟,高润霖,刘力生等. 《中国心血管病报告2016》概要[J]. 中国循环杂志,2017,32(6):521-530.
[4] Patel MR,Mahaffey KW,Garg J,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med,2011,365(10):883-891.
[5] Kirchhof P,Radaideh G,Kim YH,et al. Global prospective safety analysis of rivaroxaban[J]. J Am Coll Cardiol,2018,72(2):141-153.
[6] 裴豆豆,贾锋鹏. 心房颤动合并慢性肾脏病患者抗凝治疗现状及研究进展[J]. 心血管病学进展,2019,40(2):168-173.
[7] Coppens M,Eikelboom JW,Hart RG,et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy[J]. Eur Heart J,2013,34(3):170-176.
[8] Heidbuchel H,Verhamme P,Alings M,et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation[J]. Europace,2013,15(5):625-651.
[9] Chiang CE,Wang KL,Lip GY. Stroke prevention in atrial fibrillation:an Asian perspective[J]. Thromb Haemost,2014,111(5):789-797.
[10] Rosenstein R,Parra D. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med,2011,365(24):2334.
[11] Steffel J,Verhamme P,Potpara TS,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Eur Heart J,2018,39(16):1330-1393.
[12] Cappato R,Ezekowitz MD,Klein AL,et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation[J]. Eur Heart J,2014,35(47):3346-3355.
[13] Calkins H,Kuck KH,Cappato R,et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation:recommendations for patient selection,procedural techniques,patient management and follow-up,definitions,endpoints,and research trial design[J]. J Interv Card Electrophysiol,2012,3(2):171-257.
[14] Aryal MR,Ukaigwe A,Pandit A,et al. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation[J]. Am J Cardiol,2014,114(4):577-582.
[15] Cappato R,Marchlinski FE,Hohnloser SH,et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation[J]. Eur Heart J,2015,36(28):1805-1811.
[16] 刘晓鹏,王在义. 抗凝药物在肺栓塞治疗中的应用进展[J]. 心血管病学进展,2014(6):703-706.
[17] 李汝芳,赵芝焕. 利伐沙班在肺动脉栓塞治疗中的研究进展[J]. 实用医学杂志,2015,(9),1548-1549.
[18] EINSTEIN-PE Investigators,Buller HR,Prins MH,et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N Engl J Med,2012,366(14):1287-1297.
[19] Wang Y,Wang C,Chen Z,et al. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary em-bolism in Chinese patients:a subgroup analysis of the EINSTEIN DVT and PE studies[J]. Thromb J,2013,11(1):25.
[20] Roffi M,Patrono C,Collet JP,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2016,37(3):267-315.
[21] Angiolillo DJ,Capodanno D,Goto S. Platelet thrombin receptor antagonism and atherothrombosis[J]. Eur Heart J,2010,31(1):17-28.
[22] 赵正春,邓平. 利伐沙班在心血管疾病的研究进展[J]. 现代医药卫生,2012,28(23)3599-3600.
[23] Mega JL,Braunwald E,Wiviott SD,et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med,2012,366(1):9-19.
[24] Ohman EM,Roe MT,Steg PG,et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin,in addition to P2Y12 inhibition,in acute coronary syndromes (GEMINI-ACS-1):a double-blind,multicentre,randomised trial[J]. Lancet,2017,389(10081):1799-1808.
[25] Eikelboom JW,Connolly SJ,Bosch J,et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med,2017,377(14):1319-1330.
[26] Anand SS,Bosch J,Eikelboom JW,et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease:an international,randomised,double-blind,placebo-controlled trial[J]. Lancet,2018,391(10117):219-229.
[27] Bhagirath VC,Eikelboom JW,Anand SS. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events:an evaluation of COMPASS[J]. Future Cardiol,2018,14(6):443-453.
[28] Douxfils J,Mullier F,Loosen C,et al. Assessment of the impact of rivaroxaban on coagulation assays:laboratory recommendations for the monitoring of rivaroxaban and review of the literature[J]. Thromb Res,2012,130(6):956-966.
[29] Lindhoff-Last E,Samama MM,Ortel TL,et al. Assays for measuring rivaroxaban:their suitability and limitations[J]. Ther Drug Monit,2010,32(6):673-679.
[30] Majeed A,?gren A,Holmstr?m M,et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates:a cohort study[J]. Blood,2017,130(15):1706-1712.
相似文献/References:
[1]林莹 徐勇郭新红 刘昱圻.具有不同肌酐清除率水平的中国高龄非瓣膜性心房颤动患者应用利伐沙班的剂量选择研究[J].心血管病学进展,2019,(8):1176.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.027]
LIN Ying,XU Yong,GUO Xinhong,et al.Dose Selection of Rivaroxaban for Elderly Patients of Non-valvular Atrial Fibrillation with Different Levels of Creatinine Clearance in China[J].Advances in Cardiovascular Diseases,2019,(3):1176.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.027]
[2]李子文 刘飞 雅娟 夏云龙.肿瘤合并心房颤动的卒中风险评估及抗凝治疗[J].心血管病学进展,2020,(5):472.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.008]
LI Ziwen,LIU Fei,LIN Yajuan,et al.Stroke Risk Evaluation and Anticoagulation in Atrial Fibrillation Patients with Cancer[J].Advances in Cardiovascular Diseases,2020,(3):472.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.008]
[3]孙林芳 朱凌燕.老年心房颤动患者抗凝服药依从性及其影响因素分析[J].心血管病学进展,2020,(9):978.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.022]
SUN Linfang,ZHU Lingyan.Compliance with Anticoagulant Medication and Its Influencing Factors in Elderly Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(3):978.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.022]
[4]杨晴 梁岩.利伐沙班预防血栓的研究进展[J].心血管病学进展,2022,(10):932.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.016]
YANG Qing,LIANG Yan.Rivaroxaban in The Prevention of Thrombosis[J].Advances in Cardiovascular Diseases,2022,(3):932.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.016]
[5]向珍贤 罗素新 黄毕.瓣膜性房颤和非瓣膜性房颤的区别和抗凝策略的差异[J].心血管病学进展,2023,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
XIANG ZhenxianLUO SuxinHUANG Bi.The Difference of Definition and Anticoagulation Therapy Strategies Between Valve and Non-valve Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
[6]赵海娟 李珂 赵耀 彭玉霞 黄松群 郭志福.成人先天性心脏病合并心房颤动的诊治进展[J].心血管病学进展,2023,(3):216.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.006]
ZHAO Haijuan,LI Ke,ZHAO Yao,et al.Atrial Fibrillation in Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2023,(3):216.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.006]
[7]崔犇 陈芸霖 殷跃辉 杨仙 杨敏 易鑫.心房颤动抗凝与复律时机的抉择[J].心血管病学进展,2023,(3):229.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.009]
CUI Ben,CHEN Yunlin,YIN Yuehui,et al.Timing of Anticoagulation and Cardioversion in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(3):229.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.009]
[8]杨仙 陈芸霖 殷跃辉 易鑫 杨敏 崔犇.女性乳腺癌相关性心房颤动的研究现状[J].心血管病学进展,2023,(8):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]
YANG Xian,CHEN Yunlin,YIN Yuehui,et al.Research Status of Female Breast Cancer Associated Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(3):676.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.002]